贝伐单抗联合脂质体多柔比星和卡铂治疗复发性卵巢上皮性癌的临床研究

摘要

Objective To evaluate the efficacy and toxicity of bevacizumab combined pegy-lated liposomal doxorubicin and carboplatin in the treatment of patients with recurrent epithelial o-varian cancer.Methods Fifty patients with recurrent epithelial ovarian cancer were randomly divid-ed into test group (n =28)and control group (n =22).The patients were received the treatment with bevacizumab combined pegylated liposomal doxorubicin and carboplatin in test group,and were treated with pegylated liposomal doxorubicin and carboplatin chemotherapy in control group.Re-sults In test group,the PFS was 9.1 months,7 patients had CR,13 patients had PR,5 patients had SD,3 patients had PD,the objective response rate was 71.4%.In control group,the PFS was 7.4 months,3 patients had CR,10 patients had PR,3 patients had SD,6 patients had PD,the ob-jective response rate was 59.1%.The total response rate and the PFS in test group were remarkably highly then that in control group.The adverse events related to bevacizumab were hypertension, proteinuria and bleeding.Conclusion It is proved to be effective and safety by bevacizumab com-bined with pegylated liposomal doxombicin and carboplatin in treatment of recurrent epithelial ovari-an cancer patients.%目的：评价贝伐单抗联合脂质体多柔比星和卡铂治疗复发性卵巢上皮性癌的临床效果和安全性。方法选择2010年4月-2012年10月年本院妇产科及肿瘤科收治的复发性卵巢癌患者50例。随机分成研究组28例，对照组22例。其中研究组接受贝伐单抗联合脂质体多柔比星和卡铂方案治疗。对照组接受脂质体多柔比星和卡铂治疗。结果研究组中位疾病无进展生存时间（PFS）为9．1个月，对照组中位疾病无进展生存时间为7．4个月。研究组近期疗效总有效率（CR＋PR）为71．4％（20/28），而总临床获益率达89．2％，其中 CR 25％（7/28），PR 46．4％（13/28），SD 17．9％（5/28），PD 仅为10．8％（3/28）。对照组近期总有效率59．1％（13/22），总临床获益率72．7％，CR 13．6％（3/22），PR 45．5％（10/22），SD 13．6％（3/22），PD 27．3％（6/22）。研究组疾病无进展生存时间及有效率均高于对照组，差异有显著性。2组胃肠道反应及骨髓抑制等副反应无显著性差异，研究组有高血压、蛋白尿及出血的发生，但均为Ⅰ～Ⅱ级。结论贝伐单抗联合脂质体多柔比星和卡铂化疗对复发性卵巢上皮性癌有较高的疾病控制率，安全性较好，耐受性良好。